DENOSINE is a ubiquitous molecule that plays a pivotal role in a number of physiological and pathophysiological conditions in mammals. 49 One of the primary roles of adenosine within the cardiovascular system appears to be the direct regulation of both cardiac and vascular function. Effects of adenosine are mediated by four G protein-coupled receptors: A 1 , A 2A , A 2B , and A 3 . It is apparent that there are at least three subtypes of receptors that mediate the direct effects of adenosine in blood vessels, including the A 1 , A 2A , and A 2B subtypes. 33, 37, 41, 42, 48, 51 Activation of adenosine receptors in blood vessels can evoke either dilation or constriction, depending on the type of vessel and its basal tone. 33, 37, 49 The subtype of adenosine receptor that mediates a response in a particular vascular bed remains a matter of debate.
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The adenosine A 2A receptor is purported to play a key role in vasodilatory responses in many tissues. Adenosine A 2A receptor knockout mice have been produced; they exhibit elevated blood pressure, although it is not clear if this is a central or a peripheral effect. 2 In the vasculature, adenosine A 2 receptors have been identified on both smooth muscle and endothelium, where they are associated with vasodilation. Functional evidence suggests that adenosine can mediate vasodilation via stimulation of adenosine A 2A receptors present on the endothelium. 4, 8 The adenosine A 2A receptor Attenuation of experimental subarachnoid hemorrhageinduced cerebral vasospasm by the adenosine A 2A receptor agonist CGS 21680 subtype involved in vasodilation has not been clearly identified because considerable variability in adenosine receptor function has been observed not only between species but within species. Nevertheless, it is known that a substantial portion of the vasodilation induced by adenosine may result from a direct action on smooth muscle adenosine A 2 receptors. 51 Activation of endothelial adenosine A 2 receptors in guinea pig and porcine coronary vessels may also mediate vasodilation as a result of enhanced production of NO. 1, 8, 46 Recently, adenosine has been reported to stimulate NOS in human umbilical vein endothelial cells via adenosine A 2 receptor-mediated mechanisms. 46 Li et al. 31 have shown that adenosine A 2A receptors increase and adenosine A 1 receptors decrease the production of NO by human and porcine arterial endothelial cells. In guinea pig pulmonary artery and in rat mesenteric arterial beds, however, adenosine-mediated relaxation is mediated via the A 2B receptor, and relaxation via the A 2A receptors is weak or nonexistent. 5, 43 Cerebral vasospasm is the leading cause of mortality and morbidity in patients following aneurysmal SAH; 6, 23 however, the mechanisms and adequate treatment of vasospasm remain illusive. The vasodilatory effects of A 2A receptor activation and its favorable effects on the NO pathway raise the possibility of using A 2A receptor agonists in the treatment of cerebral vasospasm after SAH, but this possibility has not been previously examined. We therefore designed this study to examine the effect of an A 2A receptor agonist, (2(4-[2-carboxyethyl]phenyl)ethylamino)-5Ј-N-ethylcarboxamidoadenosine (also known as CGS 21680), in an experimental SAH model. To elucidate the possible mechanism of A 2A receptor agonists in treating vasospasm after SAH, we also measured and analyzed the mRNA and protein levels of eNOS and iNOS in an isolated brain blood vessel, namely the BA.
Materials and Methods

Animal Preparation and General Procedures
All procedures were approved by the Institutional Animal Care and Use Committee of Kaohsiung Medical University. One hundred four Sprague-Dawley rats, each weighing between 360 and 420 g, were evenly divided into the following four groups: 1) control (no SAH); 2) SAH only; 3) SAH plus vehicle; and 4) SAH plus CGS 21680. Intraperitoneal injections of CGS 21680 (0.01 mg/kg) or vehicle were administered 5 minutes and 24 hours after induction of SAH. Eight animals from each group were killed by perfusionfixation 48 hours after SAH. The remaining 18 animals in each group were killed by perfusion 48 hours after SAH and examined for mRNA and protein expression. Experimental SAH was induced in a manner detailed in the following section.
The CGS 21680 was purchased from Sigma Aldrich and its selectivity for the adenosine A 2A receptor has been previously validated. 15, 22, 30, 33, 49, 50 The dose chosen was based on methods used in previous studies 15, 22, 30, 33, 49, 50 and on work in our own pilot studies, which demonstrated that the chosen dosage was devoid of systemic side effects such as hypotension and tachycardia. Additionally, selective A 2A receptor agonists affect not only blood vessels but circulating bone-marrow-derived cells as well. 7 
Induction of Experimental SAH
The experimental model has been previously documented. 32, 39, 47 The rats were anesthetized by an intraperitoneal injection of ketamine (75 mg/kg) and xylazine (10 mg/kg). Each animal's rectal temperature was controlled at 36 Ϯ 1˚C by using a heating pad (Harvard Apparatus). The tail artery was cannulated using a polyethylene catheter (PE-50) for blood pressure and heart rate monitoring. The animal's head was fixed in a stereotactic frame in a nose-down position, and the superior plane of the parietal bone was tilted forward by approximately 30˚. The cisterna magna was punctured percutaneously with a 25-gauge butterfly needle and 0.15 ml of cerebrospinal fluid was slowly withdrawn. Fresh autologous nonheparinized blood (0.3 ml) was withdrawn from the tail artery. Using a needle-in-needle method (inserting a 30-gauge needle into a 25-gauge butterfly needle at the junction of the needle and tube), blood was injected into the cisterna magna slowly over approximately 2 minutes. Five minutes after the injection, the butterfly needle was slowly removed to prevent leakage of the injected blood, and the study drug or vehicle was administered intraperitoneally. The rats were removed from the stereotactic frame and were positioned in ventral recumbency for 30 minutes to allow ventral blood clot formation. Body temperature was maintained at 36 Ϯ 1˚C until the animals had fully recovered.
Perfusion-Fixation
Forty-eight hours was chosen as the time point for assessment because this is the peak period of vasospasm in this animal model. 32, 39, 47 Forty-eight hours after SAH, eight animals from each group were anesthetized as described earlier. Perfusion-fixation was performed by transthoracic cannulation of the left ventricle with a 19-gauge butterfly needle, clamping of the descending thoracic aorta, and opening of the right atrium. Perfusion was begun with 300 ml of 0.1 M phosphate-buffered saline (pH 7.4) at 37˚C, followed by 200 ml of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 37˚C. The brains were then removed and immersed in the same fixative overnight at 4˚C.
Tissue Morphometric Study and Statistical Analysis
The middle third of the BA was dissected for the morphometric analysis. Cross-sections (0.5 m thick) of the BAs were cut, mounted on glass slides, and stained with 0.5% toluidine blue. Five randomly selected arterial cross-sections from each animal were analyzed, and the cross-sectional areas were measured using computer-assisted morphometry (Image 1; Universal Imaging Corp.). For group comparisons, we performed analysis of variance with the Bonferroni post hoc test. Differences were considered to be significant at a probability value less than 0.05.
Reverse Transcriptase-PCR Amplification of eNOS and iNOS mRNA
Three BAs were pooled for total RNA extraction and homogenized in 1 ml TRIzol reagent (GIBCO BRL, Life Technologies). The first cDNA strand was reverse transcribed from 5 g total RNA. The PCR primers for eNOS were forward 5Ј-GGTGGACACAAGGCT-GGCGCA-3Ј and reverse 5Ј-GAAGTAAGTGAGAGCCTGGCG-CA-3Ј, 16 and the PCR primers for iNOS were forward 5Ј-CCAAGA-ACGTGTTCACCATG-3Ј and reverse 5Ј-GAATGTCCAGGA-AGTAGGTGAGG-3Ј. 39 As an internal control we used GAPDH with the following primers: forward 5Ј-TATGATGACATCAAG-AAGGTGG-3Ј and reverse 5Ј-CACCACCCTGTTGCTGTA-3Ј. The amplification profile involved denaturation at 94˚C for 1 minute, primer annealing at 60˚C (iNOS or GAPDH) or 69˚C (eNOS) for 30 seconds, and extension at 72˚C for 1 minute; this was repeated for 30 cycles. The PCR products of eNOS, iNOS, and GAPDH were 588, 317, and 219 bp, respectively, and were observed with the aid of ultraviolet light after 2% agarose gel electrophoresis. To ensure greater accuracy, the experiment was performed in triplicate.
Western Blot Analysis of eNOS and iNOS
To each sample (each derived from pooling of three BAs), nine volumes of dissecting buffer (50 mM Tris acetate [pH 7.4], 10% sucrose, and 5 mM ethylenediaminetetraacetic acid) were added. After homogenization, the suspension was subsequently centrifuged at 16,000 rpm for 30 minutes, and the resulting pellets were resuspended, rehomogenized, and stored at Ϫ70˚C. The protein concentration was estimated using the Bio-Rad protein microassay procedure. Equal amounts of protein (20 g for eNOS and 50 g for iNOS) 53 were separated by using 7.5% sodium dodecyl sulfate-polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane by electroblotting for 1 hour (100 V). The membrane was incubated overnight at 4˚C with blocking buffer containing 5% nonfat dry milk. The blot was then incubated with eNOS or iNOS antibody (polyclonal antibody; Santa Cruz) at a 1:50 or 1:500 dilution, respectively, for 1 hour and then incubated for 1 hour with goat antirabbit immunoglobulin G (horseradish peroxidase-conjugated, Santa Cruz) at a 1:3000 dilution. Immunoreactive protein was visualized by enhanced chemiluminescence (ECL, Amersham) according to the manufacturer's specifications. To ensure greater accuracy, the experiment was performed in triplicate.
Results
General Observations
Prior to perfusion-fixation, there were no significant differences among the treatment groups in the physiological parameters that were recorded, namely body weight, pH, PaCO 2 , PaO 2 , heart rate, body temperature, and mean arterial blood pressure. A thick subarachnoid clot was observed over the basal surface of the brainstem in each animal in which SAH was induced.
Cross-Sectional Luminal Area Measurements
The cross-sectional area of the BAs was significantly reduced in animals subjected to SAH (Fig. 1) . When compared with animals in the control group, cross-sectional areas of BAs in animals in the SAH-only and SAH-plusvehicle groups were reduced by 17 and 22%, respectively. The SAH-induced reduction in arterial area was not found in animals treated with CGS 21680; instead this area was increased by 5% compared with animals in the control group (Fig. 1) . The cross-sectional areas of BAs in the SAH plus CGS 21680 group differed significantly from those in the SAH-only and SAH-plus-vehicle groups (p Ͻ 0.05 and p Ͻ 0.005, respectively). There was no significant difference between similar areas in the SAH-plus-CGS 21680 group and in the healthy animals.
Expression of iNOS and eNOS mRNA
Compared with animals in the control group, the expression of iNOS mRNA in animals subjected to SAH was increased approximately twofold (p Ͻ 0.01), whereas in animals treated with CGS 21680, iNOS mRNA expression did not increase significantly ( Fig. 2A ). There were significant differences in iNOS mRNA between the SAH-plus-CGS 21680 group and the SAH-only group (p Ͻ 0.05).
The expression of eNOS mRNA in animals in the SAHonly group decreased significantly by 35% when compared with animals in the control group; however, the expression of eNOS mRNA was significantly increased in the group treated with CGS 21680 (p Ͻ 0.01) when compared with the SAH group (Fig. 2B) . There was no significant difference in the expression of eNOS mRNA between the control group and the SAH-plus-CGS 21680 group.
Expression of iNOS and eNOS Protein
Compared with the control group, the expression of iNOS protein increased significantly in the SAH-only group (p Ͻ 0.01), but did not increase significantly in the SAHplus-CGS 21680 group. (Fig. 3A ). Significant differences in the expression of iNOS protein were observed between the SAH-plus-CGS 21680 group and the SAH-only group (p Ͻ 0.01).
The expression of eNOS protein decreased significantly in both the SAH-only and SAH-plus-vehicle groups when compared with that in the control group (p Ͻ 0.01); however, expression of this protein was significantly higher in animals treated with CGS 21680 (p Ͻ 0.01) than in animals only subjected to SAH (Fig. 3B) . There was no significant difference between the expression of eNOS protein in the control group and the SAH-plus-CGS 21680 group.
Discussion
Although cerebral vasospasm associated with SAH has been recognized for longer than 50 years, 9 it remains a major complication affecting patients with ruptured intracranial aneurysms. As no adequate treatment for cerebral vasospasm is presently available, the pathophysiological mechanisms contributing to this form of arterial dysfunction is a topic of intense experimental study. Several mechanisms may contribute to vasospasm after SAH, including impaired endothelium-dependent relaxation, production of endothelium-derived contracting factors (such as endothelin), inflammation, and impaired activity of potassium channels in cerebral blood vessels.
The production and release of potent vasoactive factors by the endothelium play a major role in the regulation of vascular tone. The most important of these substances for regulation of vascular tone is endothelium-derived relaxing factor, the labile substance that was initially described by Furchgott and Zawadzki 14 in the aorta of rabbits. Subsequent investigation has established that endothelium-derived relaxing factor is NO or a closely related compound. Nitric oxide is produced in many cell types by a family of isoenzymes known as NOS. 12 Three isoforms of NOS are frequently described: neuronal NOS, iNOS, and eNOS. Although eNOS is frequently referred to as a constitutive isoform of NOS, the level of gene expression for NOS in endothelium may be increased or decreased in response to various stimuli and under pathological conditions. 11 In contrast to eNOS, iNOS can be expressed in many cell types including vascular smooth muscle and endothelium 11, 17 and can produce much greater amounts of NO than the constitutive forms of NOS (eNOS and neuronal NOS). 28 As high concentrations of NO can be toxic to cells, either alone or in combination with the superoxide ion that produces peroxynitrite, 3 iNOS is often referred to as the "pathological" form of NOS. 35 Impaired endothelium-dependent relaxation in large cerebral arteries after experimental SAH has been demonstrated in different animal models 10, [19] [20] [21] [25] [26] [27] and in the BAs of patients after SAH. 18, 38 Several mechanisms have been proposed to account for this vascular dysfunction. Hino et al. 19 demonstrated that a reduction in the production or activity of NOS was noted after SAH and that it likely resulted from a deficiency of eNOS in vasospastic cerebral vessels following SAH. However, levels of NOS in the endothelium (determined by Western blotting) and activity of NOS in large cerebral arteries have been reported to be relatively unchanged after SAH. 24, 36 In addition, release of NO (detected using a bioassay system) has been reported to be normal after SAH. 25, 26 Rat brains with cerebral vasospasm after SAH display the presence of nitrotyrosine, implying a massive production of NO. 36 Massive NO production under stress conditions is associated with iNOS expression. The labeling of iNOS was found in endothelial cells and in vascular smooth muscle cells after SAH, 52 and pretreatment with aminoguanidine, a selective inhibitor of iNOS, ameliorated vasoconstriction after SAH. 45 The vascular action of NO depends on whether the release of NO is physiologically regulated. 24, 34 In the present study as well as in our previous work, 32 the expression of iNOS mRNA and its protein was significantly elevated in the SAH only group, which is also concordant with findings cited in other previous reports. 19, 52 Inducible NOS has been shown to be induced in the smooth muscle cells of cerebral blood vessels, 19 endothelial cells, adventitial cells, and glial networks 52 after SAH. Furthermore, iNOS inhibition has been shown to decrease cerebral vasospasm after SAH in rats, implying that iNOS may play a crucial role in vasospasm. 45, 52 An antioxidant-responsive element and a nuclear factor-B response element have been found on the promoter region of the iNOS gene, and these two elements were responsive to oxidative states. 29 Previous data illustrate that superoxide may play a vital role in the delayed onset of vasospasm in SAH. 44 In the present study, CGS 21680 treatment significantly diminished the SAH-evoked increase in iNOS mRNA expression. It is possible that antioxidative properties may mediate the effect of CGS 21680 on the increased mRNA expression of iNOS caused by SAH. Nevertheless, in the acute phase of SAH in a rat model, Park et al. 40 found that endothelial dysfunction in cerebral microvascular spasm after SAH may be related to impaired expression of iNOS protein despite an increase in its transcription. This controversial result may be due to different phases of vasospasm (acute versus delayed) and different calibers of cerebral arteries (arterioles versus large arteries) chosen for studies. Thus, further investigation is needed to clarify whether CGS 21680 diminished the SAHaugmented expression of iNOS via antioxidative effects on iNOS gene regulation and/or the level of iNOS protein expression.
In the present study, the expressions of iNOS and eNOS after SAH were upregulated and downregulated, respectively. An opposite effect of CGS 21680 on the expressions of iNOS and eNOS was also observed, preserving appropriate levels of these enzymes as in healthy vessels. The dual effects of CGS 21680 on the expression of the NOS subtype further highlights the therapeutic potential of CGS 21680 in preventing cerebral vasospasm pursuant to SAH.
The peak period of vasospasm in this rodent model is earlier than the peak period seen in humans. Nevertheless, this model was chosen because it is well suited for screening this therapy and for molecular biological studies. This agent will be further investigated in other animal models.
Conclusions
This is the first evidence demonstrating that an adenosine A 2A receptor agonist is effective in preventing SAH-induced vasospasm. The beneficial effect of adenosine A 2A receptor agonism may be, at least in part, related to the prevention of the augmentation of iNOS expression and the preservation of normal eNOS expression in cerebral vessels after SAH. Treatment with an adenosine A 2A receptor agonist holds therapeutic promise in the management of cerebral vasospasm following SAH and is meritorious of further investigation. 
